A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
| Condition(s) | Atopic Dermatitis (AD) |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD. |
| Who can participate | Inclusion Criteria: * Trial participants aged 18 years or older at baseline, with no restrictions on gender. * Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study. Exclusion Criteria: * Known history of allergic reaction to Stapokibart Injection. * Trial participants currently or plan participating in any interventional clinical trial. * Trial participants with hematologic malignancies. * Women with pregnant. * Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Chengdu Kangnuoxing Biopharma,Inc. |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2026-06-02 |
| NCT ID | NCT07544862 |
| Official listing | https://clinicaltrials.gov/study/NCT07544862 |